Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | NTSR2 | O95665 | 7/20 | 0.54 |
| ▸ | NTSR1 | P30989 | 7/20 | 0.54 |
| ▸ | NPY1R | P25929 | 2/20 | 0.53 |
| ▸ | SORT1 | Q99523 | 6/20 | 0.52 |
| ▸ | NPY2R | P49146 | 1/20 | 0.52 |
| ▸ | NPY4R | P50391 | 1/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.52 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.51 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.51 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.51 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.51 |
| ▸ | OXTR | P30559 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25845492 | 0.92 | NTSR1 (0.54) | SLC6A2NTSR2NTSR1NPY1RNPY2R | |
| SCHEMBL14930602 | 0.90 | AGTR2 (0.55) | SLC6A2NTSR2NTSR1NPY1RSORT1 | |
| SCHEMBL25845887 | 0.89 | OPRD1 (0.56) | SLC6A2NTSR2NTSR1CALCRLF2 | |
| SCHEMBL25846293 | 0.88 | NTSR1 (0.54) | SLC6A2NTSR2NTSR1NPY2RNPY4R | |
| SCHEMBL25845603 | 0.88 | NTSR1 (0.54) | SLC6A2NTSR2NTSR1NPY2RNPY4R | |
| SCHEMBL29552077 | 0.88 | AGTR2 (0.61) | SLC6A2NTSR2NTSR1NPY1RSORT1 | |
| SCHEMBL31233798 | 0.86 | SLC6A2 (0.63) | SLC6A2NTSR2NTSR1SORT1CALCRL | |
| SCHEMBL31233911 | 0.86 | SLC6A2 (0.63) | SLC6A2NTSR2NTSR1SORT1CALCRL | |
| SCHEMBL8441486 | 0.86 | KDM1A (0.54) | NTSR2NTSR1NPY1RNPY2RNPY4R | |
| SCHEMBL29541332 | 0.85 | NTSR1 (0.63) | NTSR2NTSR1NPY1RSORT1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708393-B2 | Targeted non-invasive imaging probes of EGFR expressing cells | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708393-B2 | Targeted non-invasive imaging probes of EGFR expressing cells | EGFR, ERBB2, ERBB3 | SLC6A2 2289/4885NTSR2 455/4885NTSR1 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.